U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281001) titled 'A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients' on Nov. 29.
Brief Summary: This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
HER2-positive Breast Cancer
Trastuzumab Deruxtecan
Intervention:
DRUG: T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.
T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion
Recruitment Sta...